Puma Biotechnology - PBYI Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PBYI shares.
View PBYI analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 1 year target prices for Puma Biotechnology's shares. Their PBYI share price forecasts range from $8.00 to $8.00. On average, they anticipate the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 87.8% from the stock's current price.
View analysts price targets for PBYI or view top-rated stocks among Wall Street analysts.

Puma Biotechnology's stock was trading at $3.04 at the start of the year. Since then, PBYI shares have increased by 40.1% and is now trading at $4.26.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our PBYI earnings forecast.

Puma Biotechnology, Inc. (NASDAQ:PBYI) announced its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.78. The biopharmaceutical company had revenue of $46.20 million for the quarter, compared to analysts' expectations of $53.44 million. Puma Biotechnology had a net margin of 4.50% and a trailing twelve-month return on equity of 84.14%. The company's revenue was down 9.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.79) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Puma Biotechnology's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.94%), BlackRock Inc. (4.08%), Renaissance Technologies LLC (3.94%), Armistice Capital LLC (2.19%), Kynam Capital Management LP (1.23%) and AlphaCentric Advisors LLC (0.91%). Insiders that own company stock include Alan H Auerbach, Alvin F Wong, Ann Calby Miller, Douglas M Hunt, Jay M Moyes, Langley Steinert, Maximo F Nougues, Michael Patrick Miller, Richard Paul Bryce and Troy Edward Wilson.
View institutional ownership trends.

Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PBYI stock can currently be purchased for approximately $4.26.

Puma Biotechnology (NASDAQ:PBYI) has a market capitalization of $194.43 million and generates $253.20 million in revenue each year. The biopharmaceutical company earns $-29,130,000.00 in net income (profit) each year or $0.22 on an earnings per share basis.

The company employs 196 workers across the globe.

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The official website for the company is www.pumabiotechnology.com. The biopharmaceutical company can be reached via phone at (424) 248-6500, via email at ir@pumabiotechnology.com, or via fax at 424-248-6501.